Modeling the role of IL2 in the interplay between CD4+ helper and regulatory T cells: Studying the impact of IL2 modulation therapies

International Immunology

Volumn 24, Issue 7, 2012, Pages 427-446

  García Martínez, Karina ^a   León, Kalet ^a  

^a CENTER OF MOLECULAR IMMUNOLOGY   (Cuba)

Author keywords

Dynamics of t cells; Interleukin 2 therapies; Mathematical modeling; Regulatory t cells

Indexed keywords

INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 2 RECEPTOR ANTIBODY; INTERLEUKIN 2 RECEPTOR BETA; VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIGEN ANTIBODY COMPLEX; ARTICLE; AUTOIMMUNE DISEASE; CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; CLINICAL STUDY; CONTROLLED STUDY; GRAFT REJECTION; HELPER CELL; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; IMMUNOPOTENTIATION; IMMUNOSUPPRESSIVE TREATMENT; MATHEMATICAL MODEL; MEMORY T LYMPHOCYTE; MOUSE; NONHUMAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; RECEPTOR AFFINITY; REGULATORY T LYMPHOCYTE;

ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CELL COMMUNICATION; COMPUTER SIMULATION; HUMANS; IMMUNE TOLERANCE; IMMUNOLOGIC MEMORY; IMMUNOTHERAPY; INTERLEUKIN-2; LYMPHOCYTE ACTIVATION; MODELS, IMMUNOLOGICAL; T-LYMPHOCYTES, REGULATORY;

EID: 84864022610     PISSN: 09538178     EISSN: 14602377     Source Type: Journal    
DOI: 10.1093/intimm/dxr120     Document Type: Article

References (64)

1. Kudo-Saito, C., Garnett, C. T., Wansley, E. K., Schlom, J. and Hodge, J. W. 2007. Intratumoral delivery of vector mediated IL-2 in combination with vaccine results in enhanced T cell avidity and anti-tumor activity. Cancer Immunol. Immunother. 56:1897.
2. Fishman, M., Hunter, T. B., Soliman, H. et al. 2008. Phase II trial of B7-1 (CD-86) transduced, cultured autologous tumor cell vaccine plus subcutaneous interleukin-2 for treatment of stage IV renal cell carcinoma. J. Immunother. 31:72.
3. Lin, C. T., Tsai, Y. C., He, L. et al. 2007. DNA vaccines encoding IL-2 linked to HPV-16 E7 antigen generate enhanced E7-specific CTL responses and antitumor activity. Immunol. Lett. 114:86.
4. Tarpey, I., van Loon, A. A., de Haas, N. et al. 2007. A recombinant turkey herpesvirus expressing chicken interleukin-2 increases the protection provided by in ovo vaccination with infectious bursal disease and infectious bronchitis virus. Vaccine 25:8529.
5. Davey, R. T. Jr., Murphy, R. L., Graziano, F. M. et al. 2000. Immunologic and virologic effects of subcutaneous interleukin 2 in combination with antiretroviral therapy: a randomized controlled trial. JAMA 284:183.
6. Kovacs, J. A., Vogel, S., Albert, J. M. et al. 1996. Controlled trial of interleukin-2 infusions in patients infected with the human immunodeficiency virus. N. Engl. J. Med. 335:1350.
7. Sereti, I., Martinez-Wilson, H., Metcalf, J. A. et al. 2002. Long-term effects of intermittent interleukin 2 therapy in patients with HIV infection: characterization of a novel subset of CD4(+)/CD25(+) T cells. Blood 100:2159.
8. Natarajan, V., Lempicki, R. A., Sereti, I. et al. 2002. Increased peripheral expansion of naive CD4+ Tcells in vivo after IL-2 treatment of patients with HIV infection. Proc. Natl Acad. Sci. USA 99:10712.
9. Ahmadzadeh, M. and Rosenberg, S. A. 2006. IL-2 administration increases CD4+ CD25(hi) Foxp3+ regulatory T cells in cancer patients. Blood 107:2409.
10. Montero, E., Alonso, L., Perez, R. and Lage, A. 2007. Interleukin-2 mastering regulation in cancer and autoimmunity. Ann. N. Y. Acad. Sci. 1107:239.
11. Tang, Q., Adams, J. Y., Penaranda, C. et al. 2008. Central role of defective interleukin-2 production in the triggering of islet autoimmune destruction. Immunity 28:687.
12. Grinberg-Bleyer, Y., Baeyens, A., You, S. et al. 2010. IL-2 reverses established type 1 diabetes in NOD mice by a local effect on pancreatic regulatory T cells. J. Exp. Med. 207:1871.
13. Setoguchi, R., Hori, S., Takahashi, T., Sakaguchi, S. et al. 2005. Homeostatic maintenance of natural Foxp3(+) CD25(+) CD4(+) regulatory T cells by interleukin (IL)-2 and induction of autoimmune disease by IL-2 neutralization. J. Exp. Med. 201:723.
14. Onizuka, S., Tawara, I., Shimizu, J., Sakaguchi, S., Fujita, T. and Nakayama, E. 1999. Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody. Cancer Res. 59:3128.
15. Church, A. C. 2003. Clinical advances in therapies targeting the interleukin-2 receptor. QJM 96:91.
16. Kamimura, D., Sawa, Y., Sato, M., Agung, E., Hirano, T. and Murakami, M. 2006. IL-2 in vivo activities and antitumor efficacy enhanced by an anti-IL-2 mAb. J. Immunol. 177:306.
17. Mostbock, S., Lutsiak, M. E., Milenic, D. E., Baidoo, K., Schlom, J. and Sabzevari, H. 2008. IL-2/anti-IL-2 antibody complex enhances vaccine-mediated antigen-specific CD8(+) T cell responses and increases the ratio of effector/memory CD8(+) T cells to regulatory T cells. J. Immunol. 180:5118.
18. Webster, K. E., Walters, S., Kohler, R. E. et al. 2009. In vivo expansion of T reg cells with IL-2-mAb complexes: induction of resistance to EAE and long-term acceptance of islet allografts without immunosuppression. J. Exp. Med. 206:751.
19. Boyman, O., Surh, C. D. and Sprent, J. 2006. Potential use of IL-2/ anti-IL-2 antibody immune complexes for the treatment of cancer and autoimmune disease. Expert Opin. Biol. Ther. 6:1323.
20. Boyman, O., Kovar, M., Rubinstein, M. P., Surh, C. D. and Sprent, J. 2006. Selective stimulation of T cell subsets with antibodycytokine immune complexes. Science 311:1924.
21. Smith, K. A. 1988. Interleukin-2: inception, impact, and implications. Science 240:1169.
22. Almeida, A. R., Legrand, N., Papiernik, M. and Freitas, A. A. 2002. Homeostasis of peripheral CD4+ T cells: iL-2R alpha and IL-2 shape a population of regulatory cells that controls CD4+ T cell numbers. J. Immunol. 169:4850.
23. Grinberg-Bleyer, Y., Saadoun, D., Baeyens, A. et al. 2010. Pathogenic T cells have a paradoxical protective effect in murine autoimmune diabetes by boosting Tregs. J. Clin. Invest. 120:4558.
24. Almeida, A. R., Zaragoza, B. and Freitas, A. A. 2006. Indexation as a novel mechanism of lymphocyte homeostasis: the number of CD4+CD25+ regulatory T cells is indexed to the number of IL-2-producing cells. J. Immunol. 177:192.
25. Barthlott, T., Moncrieffe, H., Veldhoen, M. et al. 2005. CD25+ CD4+ T cells compete with naive CD4+ T cells for IL-2 and exploit it for the induction of IL-10 production. Int. Immunol. 17:279.
26. Thornton, A. M. and Shevach, E. M. 1998. CD4+CD25+ immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production. J. Exp. Med. 188:287.
27. Garcia-Martinez, K. and Leon, K. 2010. Modeling the role of IL-2 in the interplay between CD4+ helper and regulatory T cells: assessing general dynamical properties. J. Theor. Biol. 262:720.
28. Wolf, M., Schimpl, A. and Hunig, T. 2001. Control of T cell hyperactivation in IL-2-deficient mice by CD4(+)CD25(-) and CD4(+)CD25(+) T cells: evidence for two distinct regulatory mechanisms. Eur. J. Immunol. 31:1637.
29. Malek, T. R., Porter, B. O., Codias, E. K., Scibelli, P. and Yu, A. 2000. Normal lymphoid homeostasis and lack of lethal autoimmunity in mice containing mature T cells with severely impaired IL-2 receptors. J. Immunol. 164:2905.
30. Williams, M. A., Tyznik, A. J. and Bevan, M. J. 2006. Interleukin-2 signals during priming are required for secondary expansion of CD8+ memory T cells. Nature 441:890.
31. Kamimura, D. and Bevan, M. J. 2007. Naive CD8+ T cells differentiate into protective memory-like cells after IL-2 anti IL-2 complex treatment in vivo. J. Exp. Med. 204:1803.
32. Zheng, S. G., Wang, J., Wang, P., Gray, J. D. and Horwitz, D. A. 2007. IL-2 is essential for TGF-beta to convert naive CD4+CD25-cells to CD25+Foxp3+ regulatory T cells and for expansion of these cells. J. Immunol. 178:2018.
33. Smith, K. A. 2006. The structure of IL2 bound to the three chains of the IL2 receptor and how signaling occurs. Med. Immunol. 5:3.
34. Smith, K. A. 2004. The quantal theory of how the immune system discriminates between "self and non-self" Med. Immunol. 3:3.
35. Kuniyasu, Y., Takahashi, T., Itoh, M., Shimizu, J., Toda, G. and Sakaguchi, S. 2000. Naturally anergic and suppressive CD25(+)CD4(+) T cells as a functionally and phenotypically distinct immunoregulatory T cell subpopulation. Int. Immunol. 12:1145.
36. Letourneau, S., Krieg, C., Pantaleo, G. and Boyman, O. 2009. IL-2- and CD25-dependent immunoregulatory mechanisms in the homeostasis of T-cell subsets. J. Allergy Clin. Immunol. 123:758.
37. Yamazaki, S., Iyoda, T., Tarbell, S. et al. 2003. Direct expansion of functional CD25+ CD4+ regulatory T cells by antigen-processing dendritic cells. J. Exp. Med. 198:235.
38. Donohue, J. H., Lotze, M. T., Robb, R. J. et al. 1984. In vivo administration of purified Jurkat-derived interleukin 2 in mice. Cancer Res. 44:1380.
39. Tao, M. H. and Morrison, S. L. 1989. Studies of aglycosylated chimeric mouse-human IgG. Role of carbohydrate in the structure and effector functions mediated by the human IgG constant region. J. Immunol. 143:2595.
40. Stoll, S., Delon, J., Brotz, T. M. and Germain, R. N. 2002. Dynamic imaging of T cell-dendritic cell interactions in lymph nodes. Science 296:1873.
41. Garcia, Z., Pradelli, E., Celli, S., Beuneu, H., Simon, A. and Bousso, P. 2007. Competition for antigen determines the stability of T cell-dendritic cell interactions during clonal expansion. Proc. Natl Acad. Sci. USA 104:4553.
42. Castellino, F., Huang, A. Y., Altan-Bonnet, G., Stoll, S., Scheinecker, C. and Germain, R. N. 2006. Chemokines enhance immunity by guiding naive CD8+ T cells to sites of CD4+ T celldendritic cell interaction. Nature 440:890.
43. Boyman, O., Letourneau, S., Krieg, C. and Sprent, J. 2009. Homeostatic proliferation and survival of naive and memory T cells. Eur. J. Immunol. 39:2088.
44. Feinerman, O., Jentsch, G., Tkach, K. E. et al. 2010. Single-cell quantification of IL-2 response by effector and regulatory T cells reveals critical plasticity in immune response. Mol. Syst. Biol. 6:437.
45. Zhang, X., Sun, S., Hwang, I., Tough, D. F. and Sprent, J. 1998. Potent and selective stimulation of memory-phenotype CD8+ T cells in vivo by IL-15. Immunity 8:591.
46. de la Rosa, M., Rutz, S., Dorninger, H. and Scheffold, A. 2004. Interleukin-2 is essential for CD4+CD25+ regulatory T cell function. Eur. J. Immunol. 34:2480.
47. Busse, D., de la Rosa, M., Hobiger, K. et al. 2010. Competing feedback loops shape IL-2 signaling between helper and regulatory T lymphocytes in cellular microenvironments. Proc. Natl Acad. Sci. USA 107:3058.
48. Fallon, E. M., Liparoto, S. F., Lee, K. J., Ciardelli, T. L. and Lauffenburger, D. A. 2000. Increased endosomal sorting of ligand to recycling enhances potency of an interleukin-2 analog. J. Biol. Chem. 275:6790.
49. Fallon, E. M. and Lauffenburger, D. A. 2000. Computational model for effects of ligand/receptor binding properties on interleukin-2 trafficking dynamics and T cell proliferation response. Biotechnol. Prog. 16:905.
50. Toda, A. and Piccirillo, C. A. 2006. Development and function of naturally occurring CD4+CD25+ regulatory T cells. J. Leukoc. Biol. 80:458.
51. Letourneau, S., van Leeuwen, E. M. and Krieg, C. 2010. IL-2/anti-IL-2 antibody complexes show strong biological activity by avoiding interaction with IL-2 receptor alpha subunit CD25. Proc. Natl Acad. Sci. USA 107:2171.
52. Blattman, J. N., Grayson, J. M., Wherry, E. J., Kaech, S. M., Smith, K. A. and Ahmed, R. 2003. Therapeutic use of IL-2 to enhance antiviral T-cell responses in vivo. Nat. Med. 9:540.
53. Cesana, G. C., DeRaffele, G. and Cohen, S. 2006. Characterization of CD4+CD25+ regulatory T cells in patients treated with high-dose interleukin-2 for metastatic melanoma or renal cell carcinoma. J. Clin. Oncol. 24:1169.
54. Sereti, I., Imamichi, H. and Natarajan, V. 2005. In vivo expansion of CD4CD45RO-CD25 T cells expressing foxP3 in IL-2-treated HIVinfected patients. J. Clin. Invest. 115:1839.
55. Sakaguchi, N., Miyai, K. and Sakaguchi, S. 1994. Ionizing radiation and autoimmunity. Induction of autoimmune disease in mice by high dose fractionated total lymphoid irradiation and its prevention by inoculating normal T cells. J. Immunol. 152:2586.
56. Heath, V. L., Saoudi, A., Seddon, B. P., Moore, N. C., Fowell, D. J. and Mason, D. W. 1996. The role of the thymus in the control of autoimmunity. J. Autoimmun. 9:241.
57. Krieg, C., Letourneau, S., Pantaleo, G. and Boyman, O. 2010. Improved IL-2 immunotherapy by selective stimulation of IL-2 receptors on lymphocytes and endothelial cells. Proc. Natl Acad. Sci. USA 107:11906.
58. Thomas-Vaslin, V., Altes, H. K., de Boer, R. J. and Klatzmann, D. 2008. Comprehensive assessment and mathematical modeling of T cell population dynamics and homeostasis. J. Immunol. 180:2240.
59. Liparoto, S. F., Myszka, D. G., Wu, Z., Goldstein, B., Laue, T. M. and Ciardelli, T. L. 2002. Analysis of the role of the interleukin-2 receptor gamma chain in ligand binding. Biochemistry 41:2543.
60. Myszka, D. G., Arulanantham, P. R., Sana, T., Wu, Z., Morton, T. A. and Ciardelli, T. L. 1996. Kinetic analysis of ligand binding to interleukin-2 receptor complexes created on an optical biosensor surface. Protein Sci. 5:2468.
61. Wu, Z., Johnson, K. W., Choi, Y. and Ciardelli, T. L. 1995. Ligand binding analysis of soluble interleukin-2 receptor complexes by surface plasmon resonance. J. Biol. Chem. 270:16045.
62. Landgraf, B. E., Goldstein, B. and Williams, D. P. 1992. Recombinant interleukin-2 analogs. Dynamic probes for receptor structure. J. Biol. Chem. 267:18511.
63. Leon, K., Faro, J. and Carneiro, J. 2004. A general mathematical framework to model generation structure in a population of asynchronously dividing cells. J. Theor. Biol. 229:455.
64. Sojka, D. K., Bruniquel, D., Schwartz, R. H. and Singh, N. J. 2004. IL-2 secretion by CD4+ T cells in vivo is rapid, transient, and influenced by TCR-specific competition. J. Immunol. 172:6136.